• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia
Clin Lymphoma Myeloma Leuk. 2023 May 11:S2152-2650(23)00140-4. doi: 10.1016/j.clml.2023.04.012. Online ahead of print.ABSTRACTTreatment outcomes for children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) remained poor despite the use of intensive chemotherapy, imatinib or dasatinib, and consolidative allogeneic hematopoietic cell transplantation. Oleverembatinib, a third-generation ABL inhibitor, was found to be highly effective and safe in adults with chronic myeloid leukemia and in some adults with relapsed or refractory Ph+ ALL. We reviewed the efficacy and safety profile of olverembatin...
Source: Clinical Lymphoma and Myeloma - June 10, 2023 Category: Cancer & Oncology Authors: Xiaolan Li Jingliao Zhang Fang Liu Tianfeng Liu Ranran Zhang Yumei Chen Ye Guo Yongjun Fang Xiaojun Xu Ching-Hon Pui Xiaofan Zhu Source Type: research

Case Report: Calpainopathy Presenting After Bone Marrow Transplantation, With Studies of Donor Genetic Content in Various Tissue Types
This report emphasizes that genetic disease should still be considered in the context of presumably acquired disease, and also demonstrates the extent of transdifferentiation of donor cells into other tissues.
Source: Frontiers in Neurology - January 11, 2021 Category: Neurology Source Type: research